

Applicant : Ann-Marie Schmidt and David Stern
Serial No.: 09/851,071
Filed : May 8, 2001
Page 5

In response, applicants without conceding the correctness of the Examiner's position but to expedite prosecution of the subject application enclose a computer diskette containing the sequence listing in computer readable form which complies with the requirements of 37 C.F.R. §1.822 and/or §1.823. Applicants attach hereto, as **Exhibit C** a paper copy of the revised computer readable form of the sequence listing. Applicants attach hereto as **Exhibit D** a Statement in Compliance with 37 C.F.R. §1.821(f) certifying that the computer readable form contains the same information as the paper copy of the sequence listing attached as **Exhibit C**. The sequence listing does not contain any new matter.

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit E**).

1. PCT International Application No. PCT/US97/21197, filed November 12, 1997, International Publication No. WO98/22138 A1, published May 28, 1998 on behalf of The Trustees of Columbia University in the City of New York;
2. Blau et al. (1995) "Molecular Medicine: Gene Therapy - A Novel Form of Drug Delivery" N. Engl. J. Med. 333(18): 1204-1207;
3. Chen, et al. (1997) "Amyloid-beta Peptide-Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating

Applicant : Ann-Marie Schmidt and David Stern
Serial No.: 09/851,071
Filed : May 8, 2001
Page 6

Factor" Proc. Natl. Acad. Sci. 94(10): 5296-5301;

4. Hori, O. et al. (1995) "The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin" J. Biol. Chem., 270(43): 25752-25761;
5. Hori et al. (1995) "The Receptor for Advanced Glycation Endproducts (RAGE) Is A Cell Surface Receptor for Amphoterin in the Developing Central Nervous System (CNS) to Promote Neurite Outgrowth" FASEB J., 9(3): A382;
6. Hori et al. (1997) "The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease" Fundam. Clin. Cardiol., 11: 311-329;
7. Gomez-Navarro et al. (1999) "Gene Therapy For Cancer" European Journal of Cancer 35(6): 867-885;
8. Kelloff et al. (1999) "Cancer Chemoprevention: Progress and Promise" European Journal of Cancer 35(14): 2031-2038;
9. Mastrangelo et al. (1996) "Gene Therapy For Human Cancer: An Essay For Clinicians" Seminars in Oncology 23(1): 4-21;
10. Mohan, P. S. et al. (1992) "Sulfoglycolipids Bind to Adhesive Protein Amphoterin (P30) in the Nervous System" Biochem. & Biophys. Research Comm., 182(2): 689-696 ;
11. Neeper , M. et al. (1992) "Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End

Applicant : Ann-Marie Schmidt and David Stern
Serial No.: 09/851,071
Filed : May 8, 2001
Page 7

Products of Proteins" J. Biol. Chem., 267(21): 14998-15004;

12. Price, J. T. et al. (1997) "The Biochemistry of Cancer Dissemination" Critical Reviews in Biochemistry and Molecular Biology, 32(3): 175-253;
13. Schmidt, A. M. et al. (1992) "Isolation and Characterization of Two Binding Proteins for Advanced Glycolation End Products from Bovine Lung Which Are Present on the Endothelial Cell Surface" J. Biol. Chem., 267 (21): 14987-14997;
14. Schmidt et al. (1997) "V-domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications" Circulation, 96(8): I37;
15. Schmidt, A. M. et al. (1998) "RAGE: A Receptor with a Taste for Multiple Ligands and Varied Pathophysiologic States" Hormones and Signaling, 1: 41-63;
16. Schmidt et al. (1999) "Activation of Receptor for Advanced Glycation End Products A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis" Circ. Res. 84: 489-497;
17. Sigh, S. P. et al (1997) "Role of Gqa in Insulin-Stimulated Glucose Uptake by C6 Glioma Cells" NeuroReport, 8:2359-2263;
18. Taguchi et al. (2000) "Blockade of RAGE-amphoterin

Applicant : Ann-Marie Schmidt and David Stern
Serial No.: 09/851,071
Filed : May 8, 2001
Page 8

Signalling Suppresses Tumour Growth and Metastases"
Nature 405: 354-360;

19. Yan, S. D. et al. (1997) "Amyloid- β Peptide-Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-colony stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" Proc. Natl. Acad. Sci. USA, 94: 5296-5301 and;
20. Yan, S. D. et al. (1996) "RAGE and Amyloid- β Peptide Neurotoxicity in Alzheimer's Disease" Nature, 382: 685-691.

The subject application is a divisional of and claims the benefit under 35 U.S.C. §120 of U.S. Serial No. 09/062,365, filed April 17, 1998. Pursuant to 37 C.F.R. §1.98(d), copies of the above-listed references 4, 10-14, 17 and 19-20 are not being provided since they were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on August 3, 1998 in connection with the U.S. Serial No. 09/062,365 which the subject application relies on for an earlier effective filing date under 35 U.S.C. §120.

PCT International Application No. PCT/US99/08427, filed July 29, 1999, is a foreign counterpart application of the subject application. A Search Report was issued on August 19, 1999 in connection with PCT International Application No. PCT/US99/08427. A copy of the Search Report is attached hereto as **Exhibit F**. Above listed references 1, 3, 5-6 and 15 were cited in the Search Report. References 1, 3, 5-6 and 15 were submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on November 17, 2000 in

Applicant : Ann-Marie Schmidt and David Stern
Serial No.: 09/851,071
Filed : May 8, 2001
Page 9

connection with U.S. Serial No. 09/062,365, filed April 17, 1998. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

Above listed references 2, 7-9, 16 and 18 were cited by the United States Patent and Trademark Office in a February 13, 2001 Office Action in connection with the U.S. Serial No. 09/062,365, filed April 17, 1998. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone either of them at the number provided below.


Applicant : Ann-Marie Schmidt and David Stern
Serial No.: 09/851,071
Filed : May 8, 2001
Page 10

Pursuant to 37 C.F.R. 1.97(b)(3), no fee, other than the \$55.00 fee for a one-month extension of time, is deemed necessary in connection with the filing of this Amendment and Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. Box Sequence



9-25-01

John P. White
Reg. No. 28,678
Spencer H. Schneider
Registration No. 45,923

Date

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400